Compare ARK Genomic Revolution ETF (ARKG) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while JPMorgan Nasdaq Equity Premium Income ETF trades at $60.08. Which is the better fit depends on your goals.
| ARKG | JEPQ | |
|---|---|---|
Sector | Sector/Thematic | Income / Options Overlay |
52-Week High | $43.57 | $61.46 |
52-Week Low | $23.09 | $53.77 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
JEPQ trades at $60.51, up 0.45% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on Nasdaq-100 exposure with a covered call strategy for income, as highlighted in recent financial media coverage. Recent dividends include $0.64 payable in July 2026, emphasizing its income-generation appeal.
The outlook for JEPQ hinges on its ability to balance Nasdaq-100 upside with income via options strategies. Key risks include capped upside during tech rallies and fee drag. Analyst sentiment is mixed, weighing high yield against potential underperformance versus the index in strong bull markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
